Algert Global LLC Immuno Gen, Inc. Transaction History

Algert Global LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$14.09 - $19.87 $2.54 Million - $3.58 Million	180,317 New	180,317 $2.86 Million
Q2 2022 Aug 15, 2022	SELL	$3.15 - $5.76 $275,184 - $503,193	-87,360 Reduced 35.0%	162,237 $730,000
Q1 2022 May 16, 2022	BUY	$4.26 - $7.48 $942,968 - $1.66 Million	221,354 Added 783.75%	249,597 $1.19 Million
Q3 2021 Nov 15, 2021	BUY	$5.02 - $6.59 $141,779 - $186,121	28,243 New	28,243 $160,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.